Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADUS Addus HomeCare	$109.43 -2.1%	$112.61	$88.96 ▼ $136.72	$2.06B	0.81	165,886 shs	141,518 shs
ARDT Ardent Health	$13.93 -3.9%	$14.05	$11.31 ▼ $20.72	$2.07B	N/A	381,128 shs	445,645 shs
CSTL Castle Biosciences	$18.87 -3.2%	$18.06	$15.45 ▼ $35.84	$563.01M	1.1	421,011 shs	300,475 shs
PGNY Progyny	$23.24 -1.0%	$21.81	$13.39 ▼ $30.42	$2.01B	1.31	1.72 million shs	657,234 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADUS Addus HomeCare	-2.08%	-2.36%	-2.99%	+8.35%	-9.11%
ARDT Ardent Health	-4.00%	+1.16%	+6.01%	+12.52%	+1,392,999,900.00%
CSTL Castle Biosciences	-3.23%	-4.50%	+0.64%	-11.24%	+0.11%
PGNY Progyny	-0.98%	-4.24%	+10.51%	+8.60%	-19.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADUS Addus HomeCare	4.9715 of 5 stars	3.6	4.0	5.0	3.6	2.5	3.1
ARDT Ardent Health	3.2435 of 5 stars	3.5	0.0	0.0	2.0	0.0	3.1
CSTL Castle Biosciences	2.2619 of 5 stars	3.5	2.0	0.0	2.4	2.5	0.0
PGNY Progyny	1.073 of 5 stars	1.3	1.0	0.0	2.8	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADUS Addus HomeCare	3.25	Buy	$142.57	30.29% Upside
ARDT Ardent Health	3.00	Buy	$20.67	48.36% Upside
CSTL Castle Biosciences	3.00	Buy	$37.00	96.08% Upside
PGNY Progyny	2.67	Moderate Buy	$24.09	3.66% Upside

Current Analyst Ratings Breakdown

Latest CSTL, ARDT, PGNY, and ADUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	PGNY Progyny	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/8/2025	PGNY Progyny	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$28.00
6/20/2025	ADUS Addus HomeCare	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$150.00
6/10/2025	ADUS Addus HomeCare	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$133.00
5/21/2025	CSTL Castle Biosciences	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$44.00 ➝ $40.00
5/20/2025	ARDT Ardent Health	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$21.00 ➝ $21.00
5/15/2025	ARDT Ardent Health	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$21.00 ➝ $21.00
5/12/2025	PGNY Progyny	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$23.00 ➝ $21.00
5/9/2025	ARDT Ardent Health	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $18.00
5/8/2025	ADUS Addus HomeCare	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$129.00 ➝ $133.00
5/6/2025	CSTL Castle Biosciences	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $35.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADUS Addus HomeCare	$1.21B	1.66	$5.28 per share	20.73	$53.52 per share	2.04
ARDT Ardent Health	$6.02B	0.33	$2.44 per share	5.71	$10.66 per share	1.31
CSTL Castle Biosciences	$332.07M	1.64	$0.95 per share	19.82	$16.28 per share	1.16
PGNY Progyny	$1.17B	1.71	$0.34 per share	68.01	$4.96 per share	4.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADUS Addus HomeCare	$73.60M	$4.43	24.70	20.42	1.58	6.52%	9.23%	6.96%	8/4/2025 (Estimated)
ARDT Ardent Health	$210.34M	$1.63	8.55	7.11	1.31	3.73%	16.07%	4.69%	8/13/2025 (Estimated)
CSTL Castle Biosciences	$18.25M	-$0.19	N/A	N/A	N/A	-1.46%	3.41%	2.95%	8/4/2025 (Estimated)
PGNY Progyny	$54.34M	$0.57	40.77	35.75	2.41	4.33%	10.90%	7.20%	8/5/2025 (Estimated)

Latest CSTL, ARDT, PGNY, and ADUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ARDT Ardent Health	$0.51	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	PGNY Progyny	$0.42	N/A	N/A	N/A	$315.70 million	N/A
8/4/2025	Q2 2025	ADUS Addus HomeCare	$1.45	N/A	N/A	N/A	$345.71 million	N/A
8/4/2025	Q2 2025	CSTL Castle Biosciences	-$0.44	N/A	N/A	N/A	$71.53 million	N/A
5/8/2025	Q1 2025	PGNY Progyny	$0.45	$0.17	-$0.28	$0.17	$307.86 million	$324.04 million
5/6/2025	Q1 2025	ARDT Ardent Health	$0.21	$0.29	+$0.08	$0.29	$1.50 billion	$1.50 billion
5/5/2025	Q1 2025	ADUS Addus HomeCare	$1.33	$1.42	+$0.09	$1.16	$341.66 million	$337.71 million
5/5/2025	Q1 2025	CSTL Castle Biosciences	-$0.08	-$0.20	-$0.12	-$0.90	$80.40 million	$87.99 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADUS Addus HomeCare	N/A	N/A	N/A	N/A	N/A
ARDT Ardent Health	N/A	N/A	N/A	N/A	N/A
CSTL Castle Biosciences	N/A	N/A	N/A	N/A	N/A
PGNY Progyny	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADUS Addus HomeCare	0.20	1.74	1.74
ARDT Ardent Health	0.70	2.12	1.98
CSTL Castle Biosciences	0.02	9.37	9.19
PGNY Progyny	N/A	2.39	2.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADUS Addus HomeCare	95.35%
ARDT Ardent Health	N/A
CSTL Castle Biosciences	92.60%
PGNY Progyny	94.93%

Insider Ownership

Company	Insider Ownership
ADUS Addus HomeCare	4.60%
ARDT Ardent Health	1.70%
CSTL Castle Biosciences	7.20%
PGNY Progyny	9.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADUS Addus HomeCare	49,703	18.40 million	17.55 million	Optionable
ARDT Ardent Health	24,900	143.04 million	140.61 million	Optionable
CSTL Castle Biosciences	540	28.87 million	26.79 million	Optionable
PGNY Progyny	310	85.72 million	77.66 million	Optionable

CSTL, ARDT, PGNY, and ADUS Headlines

Recent News About These Companies

Principal Financial Group Inc. Raises Stake in Progyny, Inc. (NASDAQ:PGNY)

July 14 at 3:51 AM | marketbeat.com

Leerink Partnrs Has Bullish Estimate for Progyny Q2 Earnings

July 13 at 2:17 AM | americanbankingnews.com

Progyny, Inc. Partners with ŌURA to Enhance Women's Health ... - Nasdaq

July 12, 2025 | nasdaq.com

FY2026 EPS Estimates for Progyny Lifted by Leerink Partnrs

July 12, 2025 | americanbankingnews.com

Leerink Partnrs Has Bullish Forecast for Progyny Q2 Earnings

July 11, 2025 | marketbeat.com

Progyny, Inc. Partners with ŌURA to Enhance Women's Health Insights Through Wearable Technology

July 10, 2025 | quiverquant.comQ

Analysts Set Expectations for Progyny FY2026 Earnings

July 10, 2025 | marketbeat.com

Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause

July 10, 2025 | globenewswire.com

Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report - Nasdaq

July 10, 2025 | nasdaq.com

Progyny, Inc. Secures $200 Million Credit Facility to Enhance Financial Flexibility and Anticipates Positive Second Quarter Results - Nasdaq

July 10, 2025 | nasdaq.com

Which Is a Better Investment, Addus HomeCare Corporation or Progyny, Inc. Stock?

July 9, 2025 | aaii.comA

1 Value Stock with Impressive Fundamentals and 2 to Turn Down

July 9, 2025 | finance.yahoo.com

Which Is a Better Investment, Progyny, Inc. or GeneDx Holdings Corp. Stock?

July 9, 2025 | aaii.comA

Leerink Partners Upgrades Progyny (PGNY)

July 9, 2025 | msn.com

Strength Seen in Progyny (PGNY): Can Its 13.2% Jump Turn into More Strength?

July 9, 2025 | zacks.com

Progyny (NASDAQ:PGNY) Raised to "Strong-Buy" at Leerink Partnrs

July 9, 2025 | marketbeat.com

Progyny rises on guidance update

July 8, 2025 | msn.com

Progyny (NASDAQ:PGNY) Trading 7.1% Higher - Here's Why

July 8, 2025 | marketbeat.com

Leerink Partners Upgrades Progyny (NASDAQ:PGNY) to "Outperform"

July 8, 2025 | marketbeat.com

Progyny, Inc. Secures $200 Million Credit Facility to Enhance Financial Flexibility and Anticipates Positive Second Quarter Results

July 8, 2025 | quiverquant.comQ

Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report

July 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL, ARDT, PGNY, and ADUS Company Descriptions

Addus HomeCare NASDAQ:ADUS

$109.43 -2.32 (-2.08%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$109.48 +0.05 (+0.04%)

As of 07/15/2025 04:14 PM Eastern

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.

Ardent Health NYSE:ARDT

$13.93 -0.56 (-3.86%)

Closing price 07/15/2025 03:59 PM Eastern

Extended Trading

$13.93 0.00 (0.00%)

As of 07/15/2025 04:24 PM Eastern

Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.

Castle Biosciences NASDAQ:CSTL

$18.87 -0.63 (-3.23%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$18.90 +0.02 (+0.13%)

As of 07/15/2025 05:02 PM Eastern

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Progyny NASDAQ:PGNY

$23.24 -0.23 (-0.98%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$23.23 -0.01 (-0.04%)

As of 07/15/2025 06:06 PM Eastern

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time